Agreed. This is great news.

Link to news on CNN Money:
http://money.cnn.com/news/newsfeeds/articles/prnewswire/LAF03807092007-1.htm
for the record

I noticed that comment too. From my perspective it appeared to be just an awkward slip. It was on the slide so he wanted to mention something about the management team, but it came out kinda weird. I bet he wasn't planning on saying it how he did. It's kind of like one of those times when your talking and then half way through the sentence your like "crap, thats not what I want to say" but it is too late to stop so you just have to keep going. Anyway, it's definitely not a big deal and will have no effect on anything.

Yeah, I found the same number:
CINN,E,Cincinnati Stock Exchange,TRADING,800-843-3924

source: http://www.allstocks.com/markets/SI/MM_A_s/MM_C_s/mm_c_s.html

I've been to that culdesac before...
Wish I could have been there today.


Oh wait, I'm not posting here anymore... back to Bioprocess Engineering 475 homework.

It lives indeed...

I tend to agree with you that this PR points to a possibility that the inlicensing strategy could have been dropped, but we still do not know for sure.
Right now it is probably better to assume that it is still in the plan until we hear otherwise.
I for one am hoping that CX-1763 is the molecule that is moving forward in place of a possible inlicense. We shall see.

Put me down at ~3000 shares. Ave price: $2.10

Bigworld,
I did the same as you. Bought more COR so my cost basis is now $2.21. Im starting to look into real estate and business ventures to use my investment money on. After about 1.5 years of doing this stock stuff I have learned a lot... one thing being that there are a lot easier ways to make money than using stocks. I have done pretty well though and I am happy that I started trading stocks. Both BMRN and COR have been great, PPHM I am still holding out on (cost basis 0.82), and CYGX I have pretty much given up on. I might still stay in stocks in the long run, but I am going to start using an automated trading system to trade with instead of doing "DD" and picking them myself. Anyways, hope all is well with you, I have to get back to my homework!

You do the math and it has been oversold today. At least buy here and then do a quick turnaround for a 5-10% gain. Or hold long and hope Stoll knows what he is doing. Im a buyer, but what do I know.

BioMarin Announces Second Quarter 2007 Financial Results

Continued Naglazyme Momentum Drives Record Revenues

Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (23:00 CET)

NOVATO, Calif., Aug. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for its second quarter ended June 30, 2007. The net loss was $3.9 million ($0.04 per share) for the second quarter of 2007, compared to a net loss of $1.3 million ($0.02 per share) for the second quarter of 2006. The net loss during the second quarter of 2007 includes $4.3 million of non-cash stock compensation expense, compared to $2.1 million of non-cash stock compensation expense during the second quarter of 2006. The results also include Orapred milestone revenue of $4.0 million recognized in the second quarter of 2007, down from the $9.2 million in milestone and license revenue that was recognized in the second quarter of 2006. The reduced Orapred milestone and license revenue contributed to the increased net loss in the second quarter of 2007 as compared to the second quarter of 2006. The net loss for the six months ended June 30, 2007 was $13.2 million ($0.14 per share), compared to a net loss of $11.1 million ($0.14 per share) for the six months ended June 30, 2006. Non-cash stock compensation expense for the six months ended June 30, 2007 and June 30, 2006 was $7.8 million and $3.8 million, respectively.

As of June 30, 2007, BioMarin had cash, cash equivalents, and short-term investments totaling $587.7 million.

"Strong Naglazyme sales for first half of 2007 are driving bottom-line results and fueling the development of our pipeline," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "Our Kuvan program is progressing on track, with three important milestones achieved recently: submission of the NDA filing, initiation of the expanded access program, and two weeks ago, receipt of priority review status. The expanded access program is actively enrolling patients, and we are hopeful that Kuvan will receive FDA approval by the end of November."

Product Sales

Net sales of Naglazyme(R) (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), were $20.9 million for the second quarter of 2007, compared to $18.4 million for the first quarter of 2007, representing a sequential increase of approximately 13.6 percent. Naglazyme net sales for the second quarter of 2006 were $10.3 million. Net sales of Naglazyme for the six months ended June 30, 2007 were $39.3 million, an increase of $22.0 million from net sales of $17.3 million for the six months ended June 30, 2006. BioMarin is commercializing Naglazyme in the United States, Europe, and Latin America, and through distributors in other international markets.

Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC increased by approximately 23.8 percent to $29.1 million for the second quarter of 2007, compared to $23.5 million in the second quarter of 2006. Aldurazyme net sales for the first quarter of 2007 were $26.8 million. Net sales of Aldurazyme for the six months ended June 30, 2007 were $55.9 million, compared to net sales of $44.9 million for the six months ended June 30, 2006. BioMarin's share of the profit of BioMarin/Genzyme LLC was $6.6 million for the second quarter of 2007, compared to a profit of $4.7 million for the second quarter of 2006. For the six months ended June 30, 2007, BioMarin's share of the profit of BioMarin/Genzyme LLC was $12.7 million, compared to a profit of $8.5 million for the six months ended June 30, 2006.

Royalty and License Revenues

Royalty and license revenues for the second quarter of 2007 were $4.4 million, and include royalties on net product sales of the Orapred product line, including Orapred(R) (prednisolone sodium phosphate oral solution) and Orapred ODT(TM) (prednisolone sodium phosphate orally disintegrating tablets). This also includes a milestone payment of $4.0 million on the first anniversary of FDA approval of Orapred ODT in June 2007. Royalty and license revenues for the second quarter of 2006 were $9.4 million and include a $7.5 million milestone payment related to FDA approval of the marketing application for Orapred ODT. Royalty and license revenues for the six months ended June 30, 2007 were $4.8 million, compared to $9.7 million for the six months ended June 30, 2006.

2007 Financial Guidance Maintained

BioMarin estimates 2007 net sales of Naglazyme to be in the range of $76 million to $82 million. Sales of Aldurazyme by the joint venture for 2007 are expected to be in the range of $115 million to $125 million. BioMarin estimates its GAAP net loss for the fiscal year ending December 31, 2007 to be in the range of $18 million to $23 million. This includes approximately $16 million to $18 million in non-cash stock compensation expense.

Anticipated Upcoming Milestones

* Q307: Initiation of investigator-sponsored pulmonary arterial hypertension study
* Q407: Receipt of $15 million milestone payment related to Merck Serono Kuvan MAA filing
* Q407: Decision on the Kuvan NDA by the FDA
* Q407: Phenylase IND filing

Upcoming Investor Conferences

* September 10-11: Bear Stearns 20th Annual Healthcare Conference -- New York City
* September 18-20: Merrill Lynch Global Pharma, Biotech, Medtech Conference -- London

BioMarin will host a conference call and webcast to discuss second quarter 2007 financial results today, Tuesday, August 7, at 5:00 p.m. ET (23:00 CET). This event can be accessed on the investor section of the BioMarin website at http://www.BMRN.com.


Date: August 7, 2007
Time: 5:00 p.m. ET (23:00 CET)
U.S. / Canada Dial-in Number: 800.510.9836
International Dial-in Number: 617.614.3670
Participant Code: 92042653
Replay Dial-in Number: 888.286.8010
Replay International Dial-in Number: 617.801.6888
Replay Code: 30005812

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Kuvan(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the sales expectations of BioMarin's product Naglazyme and BioMarin/Genzyme LLC's product Aldurazyme; Sciele Pharma's commercialization of Orapred ODT; the financial performance of the BioMarin as a whole; the timing of BioMarin's clinical trials of 6R-BH4 for other indications; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, and 6R-BH4 for other indications; actions by regulatory authorities, including actions related to Kuvan, and 6R-BH4 for other indications; and expectations regarding actions by Merck Serono related to filing the marketing authorization application for Kuvan. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme; our joint venture partner's success in continuing the commercialization of Aldurazyme; Sciele Pharma's success in commercializing Orapred ODT; results and timing of current and planned preclinical studies and clinical trials; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme and Orapred ODT; actual sales of Aldurazyme, Naglazyme and Orapred ODT; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) and Naglazyme(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.

Net Product Sales of BioMarin Pharmaceutical Inc. and BioMarin/Genzyme LLC
For the Three and Six Months Ended June 30, 2006 and 2007
(In millions, unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
2006 2007 2006 2007
Aldurazyme (as reported by
BioMarin/Genzyme LLC) (1) $23.5 $29.1 $44.9 $55.9
Naglazyme 10.3 20.9 17.3 39.3


(1) The Company recognizes its 50% share of the net income of
BioMarin/Genzyme LLC as Equity in the income of BioMarin/Genzyme LLC
in the Company's consolidated statements of operations.



BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three and Six Months Ended, June 30, 2006 and 2007
(In thousands, except for per share data, unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
2006 2007 2006 2007

Revenues:
Net product sales $9,657 $20,941 $18,636 $39,276
Collaborative agreement
revenues 4,435 3,505 8,949 7,652
Royalty and license
revenues 9,358 4,438 9,677 4,795
Total revenues 23,450 28,884 37,262 51,723
Operating expenses:
Cost of sales (excludes
amortization of
developed product
technology) 789 4,557 2,512 8,674
Research and
development 15,779 19,186 28,058 37,345
Selling, general
and administrative 11,871 17,649 22,767 33,935
Amortization of
acquired intangible
assets 1,093 1,093 1,466 2,185
Total operating
expenses 29,532 42,485 54,803 82,139
Loss from operations (6,082) (13,601) (17,541) (30,416)
Equity in the income of
BioMarin/Genzyme LLC 4,745 6,550 8,545 12,713
Interest income 4,034 6,907 4,736 10,601
Interest expense (4,022) (3,720) (6,846) (6,055)
Net loss $(1,325) $(3,864) $(11,106) $(13,157)
Net loss per share,
basic and diluted $(0.02) $(0.04) $(0.14) $(0.14)
Weighted average common
shares outstanding,
basic and diluted 85,341 95,796 80,181 95,180



BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
December 31, 2006 and June 30, 2007
(In thousands, except for share and per share data)

December 31, June 30,
2006 2007
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $89,162 $205,010
Short-term investments 199,685 382,700
Accounts receivable, net 14,670 15,900
Advances to BioMarin/Genzyme LLC 1,596 1,302
Inventory 25,075 30,714
Other current assets 4,036 5,306
Total current assets 334,224 640,932
Investment in BioMarin/Genzyme LLC 31,457 33,269
Property, plant and equipment, net 55,466 58,780
Acquired intangible assets, net 11,655 9,470
Goodwill 21,262 21,262
Restricted cash 1,731 3,103
Other assets 7,641 14,823
Total assets $463,436 $781,639


LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $32,166 $30,604
Current portion of acquisition
obligation, net of discount 6,787 6,785
Current portion of deferred revenue 7,092 7,154
Total current liabilities 46,045 44,543
Convertible debt 223,940 497,375
Long-term portion of acquisition
obligation, net of discount 68,548 67,332
Deferred revenue, net of current portion 5,023 1,509
Other long-term liabilities 2,078 3,278
Total liabilities 345,634 614,037
Stockholders' equity:
Common stock, $0.001 par value:
150,000,000 and 250,000,000 shares
authorized at December 31, 2006 and
June 30, 2007, respectively; 91,725,528
and 95,901,593 shares issued and
outstanding at December 31, 2006 and
June 30, 2007, respectively 92 96
Additional paid-in capital 709,359 772,297
Accumulated other comprehensive loss (25) (7)
Accumulated deficit (591,624) (604,784)
Total stockholders' equity 117,802 167,602
Total liabilities and
stockholders' equity $463,436 $781,639

SOURCE BioMarin Pharmaceutical Inc. - 08/07/2007

CONTACT:
investors, Eugenia Shen, +1-415-506-6570,
or media, Susan Berg, +1-415-506-6594,
both of BioMarin Pharmaceutical Inc.
Web site: http://www.bmrn.com

I would definitely be there, except tomorrow is my last day here in Houston. Time to head back up to Washington and start school again. Ive taken the last 15 months off from school working for BP twice and Genentech once, so I will have to get back in the groove of studying. Senior year, should be a blast!

BioMarin to Host Second Quarter 2007 Financial Results Conference Call and Webcast on Tuesday, August 7 at 5:00 p.m. ET (23:00 CET)

BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Tuesday, August 7, at 5:00 p.m. ET (23:00 CET) to discuss second quarter 2007 financial results.

What: BioMarin Second Quarter 2007 Financial Results Conference Call
and Webcast

When: Tuesday, August 7, 2007 at 5:00 p.m. ET (23:00 CET)
U.S. / Canada Dial-in Number: 800.510.9836
International Dial-in Number: 617.614.3670
Participant Code: 92042653
Replay Dial-in Number: 888.286.8010
Replay International Dial-in Number: 617.801.6888
Replay Code: 30005812


Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for at least one week following the call.

It might be tough getting it at a discount. Even with the stock market hammered, BMRN held its own.

You bring up some good points gfp927z. I am not sure if we will see a pre-approval runup (like anything really fast paced), but I do expect to see a slow steady movement upward like we have been seeing over the past year.

I do expect to see an upward bump if our earnings result (which come out on the 7th) beat the estimate of -.06 per share. Last quarters release beat the estimate (-.11) by 1 cent (-.10) and it resulted in a quick bump of just under 4% and then the long streak to just under $19 (a ~17% runup).

Another bump I see in the future will come from both good BR3 clinical trial results and also approval of Kuvan (even though it is expected). We had a 2.5% bump just from receiving priority review status from the FDA.

Just because it is fun to make predictions, here is what I see happening in the near future:

Year End SP Prediction:
if Kuvan is approved, Phenylase IND is filed, and at least 1 BR3 trial has good results : $23
if Kuvan is approved, Phenylase IND is filed, and there is bad BR3 trial results: $18
if Kuvan is not approved: dont want to think about it

OT: yes, if you use Mozilla Firefox and download Adblock Plus (all free). Then there are no more ads and no more underlined annoyances.

OT: Thanks all for the advice for my future. I definitely have a lot to think about. Im sure I will let you know what I end up doing. As far as cute grad school girls go... you dont have to be in grad school to go after them.





Thought of the day:
Sometimes it is good to be unAmerican, America is not perfect.

OT: I have three more weeks in Houston with BP and then I head back to Washington for my final year in school. The tough decision now is going to be what to do after school is over. My three big choices are biotech, oil, or stay for masters/PhD. Working for oil is definitely the most tempting, due to the money and available locations.
I was expecting to have a hot and humid summer here in Houston, but so far all I have experienced is rain and lighting storms. A soccer field across from my house is under 4 feet of water and out of the past three weeks I have seen lightning and rain 15 out of the last 21 days.

Note to Bigworld:
Nice job with Cortex today! It is nice to finally see some good things heading towards at least one of my biotech holdings. Now if PPHM could just hurry up and join rank.

Congrats to all! Today is great news. Now lets see some options become available please...

Bigworld, what are your thoughts on PPHM's newest PR?

Thanks oldguy, that is indeed a very important lesson. How to spend money...
I love hearing your stories, keep them coming if you dont mind and if the board mods dont mind a few OTs

OT: Sorry for the off topic, but I do have a question for you Old guy. I only ask because you seem open and very sure of yourself. What is it like being so close to the end of your life (on earth)? Our society tiptoes around death so much and avoids talking about it, but interestingly enough it is pretty much the only thing that everyone will experience. I would love to hear your perspective on this oldguy. Fears, hopes, emotions, anything. If you feel more comfortable, you can email me (let me know and I will give you my address). Or if you dont want to talk about it I understand as well. Cheers!

Thank you! eom

I totally agree with you. Some have said that they think that the FDA "go" decision is already built into the price, but I think that is wrong. A lot of people are going to get in once/if the FDA makes a yes decision on expanding the dose limitations. There will be a jump. The stock price will climb if we hear positive news. Hooray for COR.

Options: How long does a stock have to be above $3 for some options to be offered? I think a $3 option straddle would be a great investment right about now.

Two hedge fund heavyweights, SAC Capital and Citadel, bought up shares of biotech company BioMarin Pharmaceutical. Monday, SAC Capital disclosed it owns a 5.1% "passive" stake in the company, and Citadel disclosed a 5.5% "passive" stake in the company. The company's shares gained 23 cents, or 1.3%, closing at $18.01.

This is just a confirmation of old news that has been known for a while. Nothing new or surprising to speak about here...

BioMarin Initiates Expanded Access Program for Kuvan in the U.S.
Monday June 18, 9:00 am ET

NOVATO, Calif., June 18 --BioMarin Pharmaceutical Inc. announced today that the first patient has initiated treatment in the expanded access program for Kuvan(TM) (sapropterin dihydrochloride), an investigational oral small molecule for the treatment of phenylketonuria (PKU), a rare genetic metabolic disorder. BioMarin submitted a new drug application (NDA) for Kuvan to the U.S. Food and Drug Administration (FDA) in May, and, if granted priority review status, Kuvan could receive approval by the end of 2007. Kuvan is being developed in partnership with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

"Since elevated Phe levels are toxic to the brain, it is crucial that we have a good tool to lower Phe levels in PKU patients," said lead Kuvan investigator, Dr. Barbara Burton, Director of the PKU Program at Children's Memorial Hospital in Chicago and Professor of Pediatrics, Northwestern University's Feinberg School of Medicine. "In clinical trials, Kuvan has been shown to reduce blood Phe levels and increase Phe tolerance in some PKU patients with mild, moderate and severe disease. The drug was well-tolerated across a broad spectrum of PKU patients. We look forward to the availability of Kuvan as a treatment option for PKU patients, pending FDA approval, and we are pleased to be able to provide the drug to some patients through the expanded access program in the interim."

Under an expanded access program, the FDA allows early access to investigational drugs that are being developed to treat serious diseases for which there is no satisfactory alternative therapy. BioMarin will provide Kuvan at no charge to participating patients throughout the duration of the program, which has been allowed by the FDA for patients over eight years of age with a confirmed diagnosis of PKU. The starting dose is 20 mg/kg/day, with dose adjustments allowed at the discretion of prescribing physicians between 5 mg/kg/day and 20 mg/kg/day. At least 500 PKU patients in the U.S. will be guaranteed enrollment in the program. To date, more than 70 medical facilities have submitted applications for inclusion in the expanded access program. Patients and parents of PKU patients who are interested in this program should speak with their physician or call 1-877-811-7327.

Here is a more permanent link to the same pdf:

http://www.mediafire.com/?9zr3jxfngrd

Excellent update and general overview of Biomarin:
http://www.zacks.com/newsroom/commentary/index_pdf.php?id=5251

Bull of the Day for Jun 18, 2007

BioMarin to Present at the NASDAQ 19th Investor Program
Tuesday June 12, 4:00 pm ET


NOVATO, Calif., June 12 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN - News News) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the NASDAQ 19th Investor Program in London on Tuesday, June 19, 2007 at 10:15 a.m. BST (5:15 am EDT).
Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

Jimmy Joe, I just sent you an email.

Hey Wawh! Thanks a lot for the PM. I dont have a paying account so I cant respond to it privately. But it really means a lot to me what you said.

So do you own Biomarin as well? Things are looking very up for BMRN, at least from my perspective. Sales should be on the high end of the estimates or possibly over this year, from the last conference call we had. (should be a few posts before this one if you want to listen to it). Also, with Kuvan being prepped for launch I am guessing it is only a matter of time before this company starts earning a net positive profit, probably by end of next year. I see $25 very easily by years end and higher after that.

Hopefully PPHM will do as well too. Once they start their phase II clinicals this summer, I am guessing the company is never going to be the same (in a good way). Also, I am very interested in hearing about their financing deal. Supposedly it is going to be non-equity, or non-diluting, or some amazing partnership, or something good. I sure hope so. I am waiting until it gets to $2 to see if I should hold onto PPHM long term, or bail with a 2 bagger.

As far as CYGX, I found out today that I can't attend the SHM. I am leaving tomorrow morning at 6am to go offshore (on a boat in the middle of the ocean) for almost 2 weeks. So that is pretty disappointing because after my tour I was planning on attending it. Oh well, what can you do!?

I hope you will continue to post over here especially if you are big into BMRN. Cheers and blessings to you!

Good evening everyone! Wow, I post one goodbye message and all sorts of crazy ideas start going around. You all have way too wild of an imagination! Lol

First, I am not the new CEO, nor am I employed by Cytogenix, and no, I did not sign a non-disclosure agreement. Obviously then, I choose by my own free will not to share the details of my tour. I wasn’t forced to be quiet and I didn’t learn anything secret that I cant share. Common now, you think that Malcolm would sit down with a 22 year old student and share his secrets or tell me anything that would require an NDA? I choose not to because I want to uphold my integrity / trust with Malcolm by not blabbing or repeating everything of my conversation with him.

During my tour, my outlook on Cytogenix quickly changed. I realized that this company is not just an investment or some mystical four letter symbol on a stock exchange, but rather a group of devoted individuals. I had somehow not fully realized that Cytogenix actually has people. Real, live, breathing, loving, individuals with dreams and families and all the mushy stuff. I really respect that Malcolm took me in, showed me around and gave me the time of day to talk about the company. He is genuinely a good guy and was helpful in answering all of my questions and really explaining the company’s philosophies and outlooks. In light of all this, I do not feel it would be right to post our dialog on the world wide web and disqualify myself from the trust that the people at Cytogenix showed me. I do not want to be an insincere person.

I hope you all respect my decision. Realize that you guys really are discussing some things that are connected to people’s dreams, passions, and lives. The people I met there were very nice, super intelligent, and passionate about the research they are doing. The anonymous nature of the internet makes it all too easy to disassociate the people from the company and it also allows us to create some sort of false identity that does not reflect our true character. I know I am guilty of this.

Whether Cytogenix as a company makes it in the long run, I really have no idea. I definitely left that meeting with more knowledge about what is going on and the big picture of things, but in the end, a lot of things have to line up for this to be successful. Just like the struggles of any company. I sure hope it all works and I'm in it for the long haul.

As for me leaving this message board, I figured it was a good time to go. I had been thinking about leaving, and I knew that if I stayed now and didn’t disclose all the details of my tour, then I would have been hassled to no end by some of you. This message board has been a good community, and it has been fun, but I do not see any further value in posting or being involved. This message board is good for mulling over and discussing different ideas, and for a good laugh every once in a while, but there is just too much bullcrap on here to really help my investment decisions. I will continue to read when time allows and I will stay in touch with the few individuals I have come to trust when any investment questions arise. A specific thank you to Bigworld, who is clearly an intelligent, critically thinking individual who I greatly respect and appreciate!

Best of luck, hugs and kisses, good night, sweet dreams, a bientot, and cheers to all!!

Fearfrost, just another human

PS… if you all don’t know what PCR is then maybe you are investing in the wrong area

Bank of America Health Conference: Biomarin Update

replay can be found at:
http://www.veracast.com/webcasts/bas/healthcare07/id25302614.cfm

Aloha to all. Today I went on a very nice tour of Cytogenix. I got the chance to talk with Malcolm for almost a full hour. He also showed me around and I got to see the synDNA machine and meet quite a few of the scientists. It definitely was a fun way to spend my afternoon.

And with that, I say goodbye. I will no longer be an active poster on this message board. Thanks for all the great discussions and help teaching me about stocks and investing in general. Realize that I am not selling my CYGX shares and I plan to continue my interest in Cytogenix. Maybe I will see a few of you at the share holders meeting. Best of luck to all!!

~fearfrost~

Hey Bigworld, nice move by PPHM indeed. My tour is tomorrow, so I can't answer those questions yet. I had to work today, but Fridays are off for me. i'll let you know how it goes. Cheers!

-**-
After talking with Malcolm today, I realized that he is a very nice guy to talk to on the phone. He has returned all my calls (and promptly too), and he was more than happy to let me come and visit for a tour. I offered to take him out to lunch, but he opted for the tour instead. I told him a bit about my background, he said that it was excellent I was invested with CYGX, and he said he looked forward to meeting me. I'm impressed and pretty excited to go. I have been following CYGX for almost a year and a half now so it will be sweet to actually see what I have been reading about. Anyways, it should be fun.

BTW, Houston is probably one of my favorite cities. There have been huge thunderstorms here coming and going the past 5 days. I love rain and lighting.

so it's official

IGOATOC

I still have that nice question list y'all sent me so I will come prepared with a small list of the important ones. Hopefully I will get to see the synDNA machine and meet some of the scientists. Man, the way the price is today it's tempting to buy some more shares. Buy at 0.33 and sell at 0.40 is a cool 20%. I could live with that.